Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

Introduction Real‐world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods We analysed efficacy and safety outcomes in patients ≥ 75 years from the French RetrosTECtive cohort. Among 303 patients, 90 were aged ≥ 75 years and compared with 213 younger patients. Results Elderly patients had fewer high‐risk cytogenetic abnormalities and a longer disease history. Remarkably, teclistamab appeared more effective in this population, with 74% achieving at least a very good partial response, compared with 62% of younger patients. Median progression‐free survival was 15.1 months in the elderly cohort versus 12.4 months in younger patients. Conclusion This improved efficacy did not come at the cost of increased toxicity: adverse event rates were comparable, although older patients more frequently received prophylactic measures. These findings support teclistamab as a safe and effective therapeutic option for geriatric patients with R/R MM. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.